Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, weight loss
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years.
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding pharmacies to continue selling cheaper copycat versions—at least for now.
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA said it would reconsider its previous decision to remove tirzepatide, the active compound in the weight loss and diabetes drugs Mounjaro and Zepbound, from its shortage list.
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration
tyla
1d
Gynaecologist issues warning over how weight loss drugs could affect your vagina
"Additionally, GLP-1 agonists can cause gastrointestinal side effects like nausea, vomiting, and diarrhoea. These symptoms ...
2d
on MSN
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
1d
on MSN
Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Judge unseals new evidence
Preliminary cause of death
Retiring after 15 seasons
Sells for $9M at auction
Donations drop 15%
Texas AG sues doctor
School shooting indictment
Musk's first Trump event
Teen anti-sextortion push
‘Full Self-Driving’ probe
OK classroom Bible suit
988 Lifeline georouting
Dow closes at record high
NYC giant pigeon sculpture
La Nina could arrive soon
US charges ex-Indian spy
Eases voting rules
Three Americans detained
PG&E shuts off power
Sued for alleged misconduct
TX top court halts execution
Calif. oil refinery closure
Space export curbs eased
Hyundai recalls vehicles
Afghan man denied release
Nevada US Senate debate
Teen tobacco use falls
At decade-high level
Related topics
Mounjaro
Food and Drug Administration
Zepbound
Feedback